CLDN6 CAR-T cell frequency over time in all treated patients.
DSRCT, cancer of unknown primary, CUP, serous carcinoma, Cancers
DESMOPLASTIC SMALL ROUND CELL TUMOR, FALLOPIAN TUBE, GERM CELL TUMOR, SEROUS CARCINOMA, ENDOMETRIAL CARCINOMA, EPITHELIAL OVARIAN CANCER, CANCERS, GASTRIC ADENOCARCINOMA
CAR-T cell engraftment and kinetics was recorded in all treated patients (n = 22) from day of ACT until end of FU or data cut-off. Assessments ongoing at the time of data cut-off are marked by arrowhead. Patients are grouped by cohorts at indicated DL (solid line) including the two patients treated with ‘<DL1’ or with ‘50% LD’. Redosing of patients occurred at same DL in combination with CARVac either with (*, n = 4) or without (**, n = 1) LD. Crossover at DL2 (n = 2) is indicated by circle at start of additional CARVac treatment. CAR-T cells were detected in peripheral blood using quantitative PCR on DNA isolated from PBMCs. CAR-T frequency was calculated as CAR copy number divided by µg DNA of the sample. Cancers of ‘other’ origin than GCT and EOC were each a single case of DSRCT, GC, serous carcinoma of the fallopian tube, endometrial carcinoma and CUP. ACT, adoptive cell transfer; CUP, cancer of unknown primary; DL, dose level; DSRCT, desmoplastic small round cell tumor; EOC, epithelial ovarian cancer; FU, follow-up; GC, gastric adenocarcinoma; GCT, germ cell tumor; LD, lymphodepleting chemotherapy.
